Promedior announced that it has initiated a Phase 2a clinical trial of PRM-151 for the prevention of post-surgical scarring in glaucoma patients. The Phase 2a trial will be a multicenter, randomized, double-blind, placebo controlled study that will evaluate the efficacy, safety and tolerability of PRM-151 in approximately 130 patients. The primary efficacy endpoints are improvement and maintenance of intraocular pressure and reduction in post-surgical scarring as assessed by optical coherence tomography (OCT) and a clinical assessment scale.
PRM-151 is a recombinant protein that regulates a fundamental mechanism of the immune system and activates the body’s natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation.
For more information call (610) 560-1435 or visit www.promedior.com.